Biotech M&A has plateaued
Summary: In the drug development business, deals are as crucial as scientific breakthroughs, with profitable medicines like Keytruda and Enbrel achieving their current success through M&A.
Merck targets 2025 RSV season with antibody now under FDA review
Summary: The FDA expects to decide on Merck’s approval application for clesrovimab by early June, which could position Merck to launch the drug before next fall.
UnitedHealth Group CEO addresses Brian Thompson death, says health-care system is ‘flawed’
Summary: In a New York Times opinion piece, Witty made his first public comments since last week’s fatal shooting of Thompson.
Novo Nordisk’s Ozempic faces scrutiny over potential link to rare eye condition
Summary: Danish studies suggest Ozempic may increase the risk of the rare vision-threatening condition NAION.
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
Summary: The vaccine maker’s R&D cuts face skepticism amid continued share decline.
